TY - JOUR
T1 - Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression
AU - Harrington, William R.
AU - Sheng, Shubin
AU - Barnett, Daniel H.
AU - Petz, Larry N.
AU - Katzenellenbogen, John A.
AU - Katzenellenbogen, Benita S.
N1 - Funding Information:
This work was supported by NIH grants CA18119 and DK15556, NIH training grants T32HD07028 and T32ES07326, and The Breast Cancer Research Foundation.
PY - 2003/8/29
Y1 - 2003/8/29
N2 - Estrogens exert their regulatory transcriptional effects, which can be stimulatory or repressive, at diverse gene sites via two estrogen receptors, ERα and ERβ. Since these two ERs have different tissue distributions, ligands that have the capacity to selectively activate or inhibit these two ERs would be useful in elucidating the biology of these two receptors and might assist in the development of estrogen pharmaceuticals with improved tissue selectivity. We have developed several ligands that showed ERα or ERβ selectivity at promoter-gene sites containing consensus estrogen response elements (EREs): ERα-selective agonist (propyl-pyrazole-triol (PPT)), ERα-selective antagonist (methyl-piperidino-pyrazole (MPP)), ERβ-potency selective agonist (diarylpropionitrile (DPN)) and ERβ-selective antagonist/ERα-agonist (R,R-tetrahydrochrysene (R,R-THC)). In this study, we have examined the activity of these compounds at a range of gene sites where ER stimulates gene expression through non-consensus EREs (complement C3), or multiple half-EREs (NHE-RF/EBP50), or by tethering to DNA via other proteins (TGF β3 and progesterone receptor A/AP-1), and at gene sites where ER represses gene transcription (interleukin-6). At all of these genes, PPT showed full stimulation through ERα while displaying no agonism through ERβ. MPP antagonized estradiol actions on gene transactivation and transrepression through ERα, with little or no effect on transcription mediated through ERβ. DPN displayed subtype-selective agonism, being ca. 30-fold more potent through ERβ. R,R-THC was a complete antagonist through ERβ and displayed agonism through ERα, the level of which was promoter dependent. Because these ligands maintain their agonist or antagonist character and ER subtype-selectivity at gene sites of diverse nature, where estradiol is either stimulatory or inhibitory, these compounds should prove useful in elucidating the biological functions of ERα and ERβ.
AB - Estrogens exert their regulatory transcriptional effects, which can be stimulatory or repressive, at diverse gene sites via two estrogen receptors, ERα and ERβ. Since these two ERs have different tissue distributions, ligands that have the capacity to selectively activate or inhibit these two ERs would be useful in elucidating the biology of these two receptors and might assist in the development of estrogen pharmaceuticals with improved tissue selectivity. We have developed several ligands that showed ERα or ERβ selectivity at promoter-gene sites containing consensus estrogen response elements (EREs): ERα-selective agonist (propyl-pyrazole-triol (PPT)), ERα-selective antagonist (methyl-piperidino-pyrazole (MPP)), ERβ-potency selective agonist (diarylpropionitrile (DPN)) and ERβ-selective antagonist/ERα-agonist (R,R-tetrahydrochrysene (R,R-THC)). In this study, we have examined the activity of these compounds at a range of gene sites where ER stimulates gene expression through non-consensus EREs (complement C3), or multiple half-EREs (NHE-RF/EBP50), or by tethering to DNA via other proteins (TGF β3 and progesterone receptor A/AP-1), and at gene sites where ER represses gene transcription (interleukin-6). At all of these genes, PPT showed full stimulation through ERα while displaying no agonism through ERβ. MPP antagonized estradiol actions on gene transactivation and transrepression through ERα, with little or no effect on transcription mediated through ERβ. DPN displayed subtype-selective agonism, being ca. 30-fold more potent through ERβ. R,R-THC was a complete antagonist through ERβ and displayed agonism through ERα, the level of which was promoter dependent. Because these ligands maintain their agonist or antagonist character and ER subtype-selectivity at gene sites of diverse nature, where estradiol is either stimulatory or inhibitory, these compounds should prove useful in elucidating the biological functions of ERα and ERβ.
KW - Estrogen receptors
KW - Subtype selective ligands
KW - Transactivation
KW - Transrepression
UR - http://www.scopus.com/inward/record.url?scp=0042934090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042934090&partnerID=8YFLogxK
U2 - 10.1016/S0303-7207(03)00255-7
DO - 10.1016/S0303-7207(03)00255-7
M3 - Article
C2 - 12943986
AN - SCOPUS:0042934090
SN - 0303-7207
VL - 206
SP - 13
EP - 22
JO - Molecular and Cellular Endocrinology
JF - Molecular and Cellular Endocrinology
IS - 1-2
ER -